Using HE4 and CA125 for Diagnosing Pelvic Masses
Author Information
Author(s): Anastasi Emanuela, Granato Teresa, Coppa Anna, Manganaro Lucia, Giannini Giuseppe, Comploj Sara, Frati Luigi, Midulla Cecilia
Primary Institution: Sapienza University, Rome
Hypothesis
Can HE4 and CA125 serum concentrations improve the differential diagnosis of pelvic masses in high-risk patients?
Conclusion
The combination of HE4 and CA125 serum concentrations can enhance the accuracy of diagnosing pelvic masses in patients at high risk for ovarian cancer.
Supporting Evidence
- HE4 is expressed in early stages of ovarian cancer and can indicate disease recurrence.
- The patient had a 50% chance of being a BRCA1 mutation carrier due to family history.
- Low levels of HE4 suggested a non-malignant lesion in the patient.
- Combining HE4 and CA125 with imaging techniques improves diagnostic accuracy.
Takeaway
Doctors can use blood tests for HE4 and CA125 to help figure out if a pelvic mass is dangerous or not, especially in women with a family history of cancer.
Methodology
The study involved serum analysis of HE4 and CA125 biomarkers, pelvic ultrasound, and MRI imaging.
Limitations
The patient refused genetic testing and oncogenetic counseling, which limited the ability to assess her individual risk accurately.
Participant Demographics
A 24-year-old woman with a strong family history of breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website